I am in complete agreement with increasing the AS by 100m, so that we have a back up plan if no other financing pans out. In my opinion it is far more important that we are able to uplist, and push COVID if we get approval, than it is that we minimize dilution.

I believe we will sell Leronlimab at a discount, but not give it away for free. If we make only $100 per dose, I believe this will fund all of our other indications and allow us to consequently increase our Market cap much sooner than if we had done it without COVID. To me this is more valuable than the 14% dilution costs us:

5 million doses of Leronlimab would provide 500 million in revenue. More than enough to launch all indications.

I would be surprised if we needed to use more than a third of new shares anyway, and further if we are able to get to substantial revenue in a couple of years, I would imagine the company would buy some stock back.